Official Title
Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus
Brief Title
Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus
Protocol ID
NCT00339885
Lead Sponsor
National Human Genome Research Institute (NHGRI)
Brief Summary
The aim of the project is to positionally clone susceptibility genes for NIDDM. Patients
will be ascertained in Finland from previous health surveys and hospital discharge
records. Approximately 400 affected sib pairs will be collected. Families will be chosen
who have, at most, one parent with NIDDM no history of IDDM. A clinical examination will
be undertaken on family members and blood drawn for DNA isolation. Covariates such as
body weight, blood pressure, lipid levels and urinary albumin will also be measured. The
unaffected spouse and children of a subset of probands will be invited to undergo a
frequently-sampled intravenous glucose tolerance test (FSIGT) to measure parameters of
pancreatic function and peripheral insulin resistance (IR). A number of unrelated elderly
non-diabetic subjects will also be identified to conduct a population-based association
analysis.
The FSIGT analysis will be performed in Los Angeles. The DNA will be shipped to Bethesda
where a total genomic scan will be performed using semi-automated fluorescence-based
genotyping technology. Data from Bethesda, Los Angeles and Finland will be sent to Ann
Arbor where parametric and non-parametric methods will be used to analyse both discrete
traits such as NIDDM and intermediate traits like IR....
Detailed Description
The Finland-United States investigation of NIDDM (FUSION) study is a long-term effort to
identify susceptibility genes for Type 2 diabetes (T2D) and associated quantitative
traits. This
involves the phenotyping and DNA analysis of thousands of individuals living in Finland,
utilizing a study design that was originally based on affected sib pairs. The majority of
these samples have already been subjected to a genome scan using microsatellite markers
and the original FUSION samples. Additionally, thousands of other northern European cases
and controls have been subjected to genome-wide association (GWA) analysis and/or fine
mapping as part of the FUSION study. More recently, the opportunity provided by the
lowered sequencing costs have allowed targeted and/or whole genome sequencing of many of
these individuals.
Study Period
-
Enrollment Count
32,379 participants
Eligibility Criteria
- No eligibility criteria listed.
Filters
Genetic Variation
Diabetes
COMPLETED
CHILD
ADULT
OLDER_ADULT